Christina Schriver
About Christina Schriver
Christina Schriver is a Process Engineer II at Precision BioSciences, Inc., specializing in technical transfer activities for large molecule AAV and allogenic CAR-T therapies. She is pursuing a Masters of Engineering Management from North Carolina State University and holds a Certified Associate in Project Management (CAPM) certification.
Work at Precision BioSciences
Christina Schriver has been employed at Precision BioSciences, Inc. since 2020 as a Process Engineer II in the Manufacturing Science and Technology (MS&T) department. In this role, she focuses on technical transfer activities specifically for large molecule AAV and allogenic CAR-T therapies. Her work involves ensuring the successful transition of processes from development to production, contributing to the advancement of innovative therapies in the biotechnology sector.
Education and Expertise
Christina is currently pursuing a Masters of Engineering Management from North Carolina State University. This advanced degree complements her technical expertise in process engineering and enhances her project management skills. She holds a Certified Associate in Project Management (CAPM) certification, which further demonstrates her commitment to effective project execution and management within the engineering field.
Background
Prior to her role at Precision BioSciences, Christina worked as a Production Engineer for Cook Medical in the Endoscopy Division. She also served as a Process Engineer at Roivant Sciences and Enzyvant. Her diverse experience in the biotechnology and medical device industries has equipped her with a strong foundation in process development and technical transfer activities.
Achievements
Christina Schriver has developed a solid background in tech transfer, process development, and PIP support for large molecule assets. Her contributions in these areas have been instrumental in advancing the capabilities of the organizations she has worked with, particularly in the context of large molecule AAV and CAR-T therapies.